Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,450,245 papers from all fields of science
Search
Sign In
Create Free Account
168 HR Clonidine 0.00833 MG/HR Transdermal System
Known as:
CLONIDINE 0.2 mg in 1 d TRANSDERMAL PATCH [Clonidine]
, cloNIDine HCl 0.2 MG/Day Weekly Transdermal System
, Clonidine 0.2 mg in 1 d TRANSDERMAL PATCH
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
23 relations
Adrenergic alpha2-Agonists [MoA]
Alcohol-Induced Disorders, Nervous System
Attention deficit hyperactivity disorder
Clonidine
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
J. Rosenstock
,
C. Sorli
,
+8 authors
K. Yoon
Diabetes Care
2019
Corpus ID: 197665501
OBJECTIVE To explore the efficacy, safety, and tolerability of once-weekly efpeglenatide, a long-acting glucagon-like peptide 1…
Expand
2014
2014
Dialectical Behavior Therapy: Does It Bring About Improvements in Affect Regulation in Individuals with Eating Disorders?
Denise D. Ben-Porath
,
A. Federici
,
L. Wisniewski
,
Mark Warren
Journal of Contemporary Psychotherapy
2014
Corpus ID: 21571348
The current investigation sought to determine whether a standard outpatient dose of dialectical behavior therapy (DBT) skills…
Expand
2008
2008
P-441 weekly Carboplatin(CBDCA)/Paclitaxel(PTX)による長期の外来治療が可能であった進行肺腺癌の2例(化学療法4,第49回日本肺癌学会総会号)
広瀬 敏幸
,
吉田 卓弘
,
梶川 愛一郎
,
須見 高尚
,
杉本 友則
,
監崎 孝一郎
2008
Corpus ID: 68924729
2007
2007
A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients…
J. Spratlin
,
S. Eckhardt
,
+8 authors
R. Cohen
2007
Corpus ID: 86371263
A33 Background: VEGFR-2 is a key regulator of angiogenesis and cancer cell growth. IMC-1121B is a recombinant human IgG1 MAb…
Expand
2006
2006
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer
P. Souza
,
W. Liauw
,
M. Links
,
S. Pirabhahar
,
G. Kelly
,
L. Howes
Cancer Chemotherapy and Pharmacology
2006
Corpus ID: 25860890
Background: We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06…
Expand
2006
2006
P-458 非小細胞肺癌患者に対する weekly TJ療法の有効性に関する検討(抗癌剤・薬理動態2, 第47回日本肺癌学会総会)
陶山 久司
,
重岡 靖
,
+6 authors
清水 英治
2006
Corpus ID: 181410199
Highly Cited
2005
Highly Cited
2005
Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.
C. Tolman
,
D. Richardson
,
C. Bartlett
,
E. Will
Journal of the American Society of Nephrology
2005
Corpus ID: 26123507
In view of the recent interest in weekly erythropoietic regimens and the lack of studies directly comparing the available agents…
Expand
2004
2004
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors.
R. Ramanathan
,
D. Trump
,
+7 authors
M. Egorin
Journal of Clinical Oncology
2004
Corpus ID: 45337729
3031 Background: 17AAG is a benzoquinone antibiotic known to down regulate oncoproteins, by binding to heat shock protein 90…
Expand
2004
2004
P11-2 Gefitinib不応性もしくは抵抗性非小細胞肺癌患者に対するgefitinib, weekly paclitaxel併用療法の第II相試験(ポスター総括11 : 基礎 ゲフィチニブ(臨床))
新屋 智之
,
笠原 寿郎
,
+7 authors
中尾 眞二
2004
Corpus ID: 174552540
Highly Cited
2001
Highly Cited
2001
A Model Study of Oceanic Mechanisms Affecting Equatorial Pacific Sea Surface Temperature during the 1997–98 El Niño
J. Vialard
,
C. Menkes
,
+4 authors
G. Madec
2001
Corpus ID: 16897651
In this study, the processes affecting sea surface temperature variability over the 1992-98 period, encompassing the very strong…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE